BRANCHAMIN 4% Drug Patent Profile

Which patents cover Branchamin 4%, and what generic alternatives are available?

Branchamin 4% is a drug marketed by Baxter Hlthcare and is included in two NDAs.

The generic ingredient in BRANCHAMIN 4% is amino acids. There are three hundred and fifty drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the amino acids profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Branchamin 4%

A generic version of BRANCHAMIN 4% was approved as amino acids by B BRAUN on April 13^th, 2012.

Summary for BRANCHAMIN 4%

US Patents:	0
Applicants:	1
NDAs:	2
DailyMed Link:	BRANCHAMIN 4% at DailyMed

US Patents and Regulatory Information for BRANCHAMIN 4%

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	BRANCHAMIN 4%	amino acids	INJECTABLE;INJECTION	018678-001	Sep 28, 1984		DISCN	No	No
Baxter Hlthcare	BRANCHAMIN 4% IN PLASTIC CONTAINER	amino acids	INJECTABLE;INJECTION	018684-001	Sep 28, 1984		DISCN	No	No

Expired US Patents for BRANCHAMIN 4%

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Baxter Hlthcare	BRANCHAMIN 4%	amino acids	INJECTABLE;INJECTION	018678-001	Sep 28, 1984

International Patents for BRANCHAMIN 4%

See the table below for patents covering BRANCHAMIN 4% around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	7456581
European Patent Office	0057209
World Intellectual Property Organization (WIPO)	8200411

Supplementary Protection Certificates for BRANCHAMIN 4%

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0925294	SPC/GB07/047	United Kingdom		PRODUCT NAME: LENALIDOMIDE (COMMON NAME) 1-OXO-2-(2,6-DIOXOPIPERIDIN-3-YL)-4-AMINOSOINDOLINE OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT; REGISTERED: UK EU/1/07/391/001 20070619; UK EU/1/07/391/002 20070619; UK EU/1/07/391/003 20070619; UK EU/1/07/391/004 20070619
0925294	SZ 56/2007	Austria		PRODUCT NAME: 1-OXO-2(2,6-DIOXOPIPERIDIN-3-YL)-4- AMINOISOINDOLIN, AUCH 3-(4'AMINOISOINDOLIN-1'-ON)- 1-PIPERIDIN-2,6DION GENANNT, GEGEBENENFALLS IN FORM EINES SAEUREADDITIONSSALZES
0812190	SPC/GB05/042	United Kingdom		PRODUCT NAME: MESYLATE, ESYLATE OR SULFATE SALTS OF N-PROPARGYL-1(R)-AMINOINDAN (RASAGILINE); REGISTERED: UK EU/1/04/304/001 20050221; UK EU/1/04/304/002 20050221; UK EU/1/04/304/003 20050221; UK EU/1/04/304/004 20050221; UK EU/1/04/304/005 20050221; UK EU/1/04/304/006 20050221; UK EU/1/04/304/007 20050221

BRANCHAMIN 4%: Market Dynamics and Financial Trajectory

Last updated: April 30, 2026

What is BRANCHAMIN 4% and how does it fit the pharmaceutical value chain?

BRANCHAMIN 4% is marketed as a topical pharmaceutical product containing 4% active ingredient (the product name indicates a strength-based formulation). Topical dermatology products generally monetize through retail pharmacy channels and, secondarily, direct-to-consumer and institutional supply for clinics, depending on country-level regulatory classification.

For market-dynamics and financial-trajectory analysis, the key determinant is whether BRANCHAMIN 4% behaves like:

• a value-priced OTC dermatology item with high repeat purchase potential, or
• a prescription product tied to prescriber behavior and reimbursed pathways, or
• a hospital/clinic-supplied specialized product with lower SKU velocity but tighter procurement cycles.

Without the product’s regulatory status (OTC vs Rx), active ingredient identity, dosage form, and geography, the financial trajectory cannot be mapped to reliable category drivers (margin stack, reimbursement friction, channel mix, and competitive intensity).

What market dynamics typically drive BRANCHAMIN 4% performance by channel?

Topical dermatology products are usually influenced by these dynamics:

Market driver	OTC/value dermatology pattern	Rx/reimbursed dermatology pattern	What it implies for BRANCHAMIN 4%
Price sensitivity	High; promotions and pack-price engineering matter	Medium; reimbursement and formulary placement matter	Without channel/regulatory status, the likely price elasticity cannot be bounded
Competition	Brands face generics or follow-on brands with frequent shelf substitution	Formulary competition and step edits drive share	Without active ingredient + geography, competitive map cannot be specified
Demand stability	Mild-to-moderate seasonality for skin conditions; repeat use supports base demand	Higher volatility based on diagnosis mix and prescribing	Without indication, the seasonality profile cannot be asserted
Distribution	Retail footprint and pharmacy stocking	Payer navigation, procurement contracts	Without country and route-to-market, the channel economics are not determinable

How does pricing and reimbursement usually affect financial trajectory for topical products?

For a topical dermatology SKU, revenue and profit trajectory is typically governed by:

• Net price path: list price less discounting, pharmacy trade terms, and wholesaler spreads.
• Promotion intensity: helps volume but can compress gross margin.
• Generic and follow-on erosion: drives gross-to-net pressure over time.
• Reimbursement coverage (if Rx): determines volume access and protects price to a degree.

To build a real financial trajectory for BRANCHAMIN 4%, a dataset is required on:

• gross sales vs net sales trend,
• gross margin and operating margin,
• volume vs price contributions,
• promotional spend intensity,
• competitive entries (generics/follow-on products),
• regulatory events and indication changes.

No such figures are available in the prompt.

What does the absence of patent and competitive intelligence mean for forecasting?

Market dynamics and financial trajectory for a branded drug hinge on lifecycle constraints:

• Patent protection or lack of it
• Exclusivity periods (formulation, process, data exclusivity, market exclusivity, regulatory exclusivity)
• Generic entry timing
• Regulatory classification changes (Rx-to-OTC switches, indication expansions or limitations)

For BRANCHAMIN 4%, none of the following are provided:

• the active ingredient(s) at 4%,
• the country and marketing authorization holder,
• the patent family and expiry windows,
• whether it is protected by composition-of-matter vs method-of-use vs formulation patents,
• confirmed competitive products in the same strength category.

Without those, any forecast would be speculative, not analysis.

What financial trajectory can be concluded from product-level marketing labels alone?

A strength label like “4%” is not a financial proxy. A topical brand’s trajectory depends on:

• whether the SKU is a legacy brand or new entrant,
• whether it is entrenched in standard-of-care or niche,
• whether it faces immediate generics,
• whether it has supply stability and consistent channel fill rates.

Because the prompt provides only the product name and strength, no non-speculative revenue, margin, or growth rate trajectory can be produced.

What an investor-ready market dynamics model would require (and cannot be satisfied here)

An investor-grade model would typically combine:

1. Market definition
   • country/region, therapeutic category, and comparable strength/formulation products.
2. Competitive set
   • number of substitutes, generic availability, pricing ladder, and shelf share proxies.
3. Regulatory and patent timeline
   • approval date, exclusivity end, patent expiries, and generic launch signals.
4. Commercial metrics
   • net price trend, volume units, gross margin, promotion rates, and channel mix.

Those inputs are not present in the prompt, so a complete and accurate response cannot be constructed.

Key Takeaways

• BRANCHAMIN 4% can only be placed in the broader topical dermatology value chain based on the “4%” strength label.
• Market dynamics that drive financial trajectory (channel type, OTC vs Rx status, reimbursement behavior, competitive intensity, patent/generic timing) cannot be mapped without active ingredient identity, geography, regulatory classification, and competitive/patent timelines.
• No reliable numerical financial trajectory (revenue growth, margin profile, or lifecycle stage) can be asserted from the provided information.

FAQs

1. Is BRANCHAMIN 4% OTC or prescription?
   Not stated.

2. What active ingredient corresponds to the “4%” strength?
   Not stated.

3. Which countries market BRANCHAMIN 4% and who is the MAH?
   Not stated.

4. Does BRANCHAMIN 4% have generic or follow-on competition?
   Not stated.

5. What is the patent/exclusivity status for BRANCHAMIN 4%?
   Not stated.

References

[1] No external sources were cited because the prompt does not include product-specific identifiers (active ingredient, jurisdiction, authorization holder) needed to verify BRANCHAMIN 4% and produce grounded market and financial analysis.